CSPC Pharmaceutical Group (HKG:1093) officially initiated a phase III trial of docetaxel for injection at the first centre in China, according to a Thursday bourse filing.

The study will evaluate the safety and efficacy of the drug in patients with advanced breast cancer, the filing said.